once-daily, fixed-dose combination tablet elbasvir/grazoprevir (50 mg/100 mg) is more effective and safer than a commonly used regimen that includes sofosbuvir (400 mg) plus peginterferon and ribavirin in patients with chronic hepatitis C virus genotype 1 or genotype 4 infection, according to the results of a phase 3 trial released at the International Liver Congress 2016.
A new study shows that a once-daily tablet is more effective and safer than the current standard treatment for hepatitis C.
In the multi-center C-EDGE Head-to-Head study, investigators randomized 255 patients to 12 weeks of treatment with elbasvir (an NS5A inhibitor) plus grazoprevir (an NS3/4A protease inhibitor) or the NS5A inhibitor sofosbuvir plus peginterferon and ribavirin (PR).
The sofosbuvir plus PR regimen was recommended in guidelines at the start of the trial.
The study enrolled treatment-naive and PR treatment-experienced patients, with or without cirrhosis, with chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection.
“While direct-acting antiviral agents represent the standard-of-care treatment for HCV infection, head-to-head studies have not been reported,” said principal investigator Dr. Jan Sperl, who is a liver specialist at the Institute for Clinical and Experimental Health in Prague, Czech Republic.
Read Full Article: Hepatitis C: elbasvir/grazoprevir combo tops popular treatment – Medical News Today